Latest news with #MattPhipps
Yahoo
09-06-2025
- Business
- Yahoo
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) on Monday released topline data from pre-specified Alzheimer's Disease biomarker analyses in the Phase 3 BROADWAY clinical trial. The study was primarily designed to evaluate the efficacy of obicetrapib in lowering low-density lipoprotein cholesterol (LDL-C) in adult patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-lowering therapy. A pre-specified sub-study was conducted to assess the effect of obicetrapib on plasma biomarkers of Alzheimer's in the full study population and patients carrying the ApoE4 company plans to present the full results from the AD sub-study analysis in a Developing Topics oral presentation at the Alzheimer's Association International Conference in Toronto at the end of July 2025. The primary endpoint was the LS mean percent change from baseline in LDL-C of obicetrapib 10 mg compared to placebo after 84 days, which showed a 33% reduction with imputation. Secondary endpoints also included percent changes from baseline of obicetrapib 10 mg compared to placebo in ApoB, Lp(a), ApoA1, HDL-C, non-HDL-C, total cholesterol, and triglycerides at day 84, and on LDL-C levels at days 180 and 365. Other exploratory outcome measures included time from randomization until the first confirmed occurrence of MACE in the obicetrapib arm compared to the placebo. The trial also evaluated the safety and tolerability profile of obicetrapib. In a note to investors, the investment firm William Blair expressed continued confidence in NewAmsterdam Pharma's drug, obicetrapib, following the release of new clinical trial data. William Blair analyst Matt Phipps said, 'We continue to believe obicetrapib will offer a differentiated product profile in the marketplace, and while we have not factored in Alzheimer's benefit to our current assumptions, this could clearly provide significant long-term continue to believe seeing LDL reductions below 55% would be a positive for NewAmsterdam, particularly utilization of the fixed-dose-combination with ezetimibe.' William Blair maintained an Outperform rating on NewAmsterdam Pharma, citing a 90% probability of success for obicetrapib. The analyst has derived a fair value for NewAmsterdam shares of $43. Phipps asserted that obicetrapib could achieve a significant and clinically meaningful reduction in cardiovascular outcomes in the ongoing Phase 3 PREVAIL trial, potentially achieving a 20% or greater relative risk reduction. Price Action: NAMS stock is trading lower by 1.04% to $19.93 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
07-06-2025
- Business
- Business Insider
Analysts' Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quince Therapeutics (QNCX – Research Report) and Moderna (MRNA – Research Report). Confident Investing Starts Here: Quince Therapeutics (QNCX) In a report issued on June 4, Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics, with a price target of $6.00. The company's shares closed last Friday at $1.17. According to McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.2% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quince Therapeutics with a $6.67 average price target. Moderna (MRNA) In a report released today, Matt Phipps from William Blair reiterated a Hold rating on Moderna. The company's shares closed last Friday at $27.46. According to Phipps is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.1% and a 41.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Janux Therapeutics Inc. Currently, the analyst consensus on Moderna is a Hold with an average price target of $49.29, an 88.1% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Business Insider
05-06-2025
- Business
- Business Insider
Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)
Evercore ISI analyst maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $73.00. The company's shares closed yesterday at $67.42. Confident Investing Starts Here: In addition to Evercore ISI, Incyte also received a Hold from William Blair's Matt Phipps in a report issued yesterday. However, on the same day, BMO Capital maintained a Sell rating on Incyte (NASDAQ: INCY). Based on Incyte's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.05 billion and a net profit of $158.2 million. In comparison, last year the company earned a revenue of $880.89 million and had a net profit of $169.55 million Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year. Earlier this month, Thomas Tray, the CAO of INCY sold 1,614.00 shares for a total of $105,515.61.
CNBC
03-06-2025
- Business
- CNBC
This biotech stock rallying on cancer treatment data has more room to run, analysts say
Analysts are closely watching Merus and see more upside ahead coming out of one of the biggest biotechnology conferences in the U.S. Merus shares shot up late last month following the release of promising Phase 2 data for a treatment for head and neck cancer. This has made the Netherlands-based company the talk of the investing set that flocked to Chicago for the American Society of Clinical Oncology's annual meeting , which concludes Tuesday. "They're first in class. We think they're best in class," said Matt Phipps, group head of the biotech equity research team at William Blair. "That's just kind of a combination that a lot of investors really want to be a part of." The stock has popped about 40% in the past month and rallied to a new all-time high on Tuesday. Still, multiple analysts interviewed by CNBC Pro said Merus can surge even higher — with one even suggesting shares can more than double from current levels given there are more catalysts on the horizon. MRUS 1M mountain Merus, 1-month Phipps said Merus' data overshadowed a similar report from Bicara Therapeutics , whose shares have tumbled 24% over the past month. He said Merus' release cemented itself as the best drug in combination with Merck 's Keytruda for head and neck cancer. Guggenheim analyst Michael Schmidt said similar success in Phase 3 data could more than double the value of Merus' shares. To be sure, he noted that investors should be prepared to wait between 12 and 18 months to see this upside given the schedule for data releases that can boost the stock. Beyond that, he said the same drug combination has potential for treating colorectal cancer. While Schmidt acknowledged that its not a major focus of investors yet, he said data from ongoing Phase 2 studies expected in the second half of 2025 is something to keep an eye on. Expectations for this, he said, are "very modest." "It's a stock that we have a lot of conviction on," Schmidt said. "We like this story a lot." Multiple analysts interviewed by CNBC said the name could also be an acquisition target from bigger-name biopharmaceutical companies, which could further drive upside. That can also help explain why Wall Street is so bullish. Every analyst polled by LSEG has a buy or strong buy rating, with an average price target suggesting 45% in upside ahead. "You want to buy it now," said BMO analyst Evan Seigerman, who called the company's data "really compelling." "This is the type of company that a large pharma company would want to acquire." Seigerman said the company has both "great" clinical data and is in an area with "unmet need," which is a combination that can make the stock a winner in what he described as a competitive sector. A boost to Merck? The treatment's success can also have knock-on benefits for Merck shares given the potential sales bump for Keytruda, according to Leerink analyst Andrew Berens. Berens said Keytruda is approved as a monotherapy, but only about 20% of patients respond to it, making the average time spent on the drug about few months. But used in conjunction with Merus' product, he noted that data shows that rate shoots up to the high 60% level and increases duration to nearly a year. "It's a win-win for Merck," Berens said. "This drug has its own activity," he said, "but it also means they can sell more of their flagship drug."
Business Insider
15-05-2025
- Business
- Business Insider
William Blair Remains a Buy on Tenax Therapeutics (TENX)
In a report released today, Matt Phipps from William Blair maintained a Buy rating on Tenax Therapeutics (TENX – Research Report). The company's shares closed today at $5.68. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Phipps covers the Healthcare sector, focusing on stocks such as Incyte, Bristol-Myers Squibb, and Merus. According to TipRanks, Phipps has an average return of -10.8% and a 33.57% success rate on recommended stocks. Tenax Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.00.
